Litigation Details for In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation (D. Del. 2020)

In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation (D. Del. 2020)

Docket		Date Filed	2020-08-18
Court	District Court, D. Delaware	Date Terminated
Cause	15:15 Antitrust Litigation	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To
Patents	6,923,984
Link to Docket	External link to docket

Details for In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-12-16	135	Complaint - Amended	which are described in U.S. Pat. No. 6,923,984, incorporated herein by reference.36…follow-on patent purportedly covering Seroquel XR, U.S. Patent No. 5,948,437 (the “’437 Patent”), which… is the owner of U.S. Patent No. 4,879,288 (“the ‘288 Patent”). The ’288 Patent issued on November 7,…’637B Patent. By issuing the Handa ’637A Patent and Handa ’637B Patent despite AstraZeneca’s ’288 and…637A Patent and in the Handa ’637B Patent were patentably distinct from the compositions disclosed and	External link to document
2020-12-17	136	Complaint - Amended	are described in U.S. Pat. No. 6,923,984, incorporated herein by reference… expiration of U.S. Patent No. 5,948,437 (the “’437 Patent”), a follow-on patent, which supposedly covered…. Patents Are Not Bulletproof. 71. Patents are not bulletproof. Patents are routinely…is the owner of U.S. Patent No. 4,879,288 (“the ’288 Patent”). The ’288 Patent issued on November 7,…’637B Patent. By issuing the Handa ’637A Patent and Handa ’637B Patent despite AstraZeneca’s ’288 and	External link to document